Is HIMS a Buy? What to Consider in 2026
Short answer
The bull case for Hims & Hers Health (HIMS) rests on Recurring subscription model: Hims is built on auto-refilling monthly subscriptions rather than one-time sales, which produces predictable, compounding revenue as the base grows. Revenue (TTM) is ~$2.37 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026. Whether HIMS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Hims & Hers Health operates a direct-to-consumer telehealth platform that connects users with licensed providers and ships personalized prescription and over-the-counter products on a subscription basis. Its categories span sexual health, hair loss and dermatology, mental health, and weight management, and the model is built on recurring monthly revenue: most customers are subscribers who refill automatically, which is why the company reports subscriber counts and revenue per subscriber as core metrics. It earns money primarily through these subscriptions and increasingly through higher-priced specialty offerings, and it has invested in owning more of its supply chain, including affiliated pharmacies and a lab and peptide facility. The company was founded in 2017 by Andrew Dudum, who remains chief executive, and went public in 2021 through a merger with a special-purpose acquisition company. Hims built early scale through aggressive digital marketing around men's wellness, then expanded into women's health and broader categories. In 2024 and 2025 it rode a surge of demand for compounded GLP-1 weight-loss medication, but a 2026 dispute with Novo Nordisk reshaped that business: after litigation, the two companies reached a partnership in which Hims offers branded semaglutide and steps back from marketing compounded versions except where medically necessary.
What's the case for buying HIMS?
Recurring subscription model
Hims is built on auto-refilling monthly subscriptions rather than one-time sales, which produces predictable, compounding revenue as the base grows. Subscribers reached roughly 2.6 million in the first quarter of 2026, up about 9 percent year over year. A larger base of retained subscribers, each potentially buying more categories over time, is the core engine the bull case relies on.
Category expansion beyond the original niche
The platform started in men's sexual health and hair loss but has pushed into dermatology, mental health, women's health, weight management, and longevity-adjacent offerings. Each new condition is a chance to cross-sell existing subscribers and acquire new ones. Management has set long-range targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, which depends on this broadening working.
Vertical integration and personalization
Hims has invested in affiliated pharmacies, a lab, and peptide manufacturing to control more of its supply chain and offer personalized formulations. Owning these capabilities can support differentiated products and, over time, better unit economics. The company frames personalization as a moat that generic telehealth and pharmacy competitors struggle to copy quickly.
Branded GLP-1 partnership reset
After the 2026 conflict with Novo Nordisk, Hims now offers branded semaglutide products on its platform and has dialed back compounded GLP-1 marketing. This removes a major legal overhang and keeps Hims inside the high-demand weight-loss category. The trade-off is that reselling branded drugs typically carries thinner margins than the compounded products it sold before.
What are the risks to HIMS?
The GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026. Competition is intense and well funded, including Ro, LifeMD, Teladoc, and numerous smaller GLP-1 telehealth providers, which can raise customer-acquisition costs. Growth decelerated to roughly 4 percent year over year in the first quarter of 2026 even as the valuation stayed rich relative to current profitability, so any further slowdown or margin erosion could weigh on the stock. The company also carries dependence on a few high-demand categories and on continued heavy marketing spend.
How is HIMS valued? (as of 2026-06-27)
- Revenue (TTM): ~$2.37 billion
- Q1 2026 revenue growth (YoY): ~4%
- Gross margin: ~65% (compressed ~800 bps YoY)
- Subscribers: ~2.6 million (up ~9% YoY)
- Trailing P/E: Not meaningful (roughly breakeven to slightly negative net income TTM); forward P/E ~70x
- Market cap: ~$7-8 billion
Hims reported first-quarter 2026 revenue near $608 million with positive adjusted EBITDA of about $44 million, down roughly 51 percent year over year as gross margin compressed. Net income on a trailing basis was roughly breakeven to slightly negative, so the trailing P/E is not meaningful and the market values the company largely on growth and future profitability. Full-year 2026 guidance was set around $2.8 billion to $3.0 billion in revenue. All figures are approximate and tied to the asOf date; check a current quote and the latest filing before relying on them.
How do you decide if HIMS is a buy?
Rather than asking whether HIMS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold HIMS indirectly through an index or sector ETF before adding more.
For the full picture, see the HIMS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HIMS against your real portfolio and see your actual exposure before deciding.
The bottom line on HIMS
The bottom line: Hims & Hers Health's story right now is Recurring subscription model, with revenue (ttm) at ~$2.37 billion. If you believe that narrative continues, the call is about sizing HIMS sensibly and checking overlap with what you own; if you doubt it (the risk: the GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around HIMS with Walnut
Use Hims & Hers Health as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is HIMS a good stock to buy right now?
+
The case for Hims & Hers Health right now is Recurring subscription model, with revenue (ttm) at ~$2.37 billion. If you believe that thesis holds, HIMS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Hims & Hers Health do?
+
Hims & Hers Health operates a direct-to-consumer telehealth platform that connects users with licensed providers and ships personalized prescription and over-the-counter products o
What are the main risks of HIMS?
+
The GLP-1 category is the clearest risk: the shift from cheaper compounded semaglutide to branded resale, plus ongoing FDA scrutiny of telehealth compounding and marketing claims, can pressure both growth and gross margins, which compressed sharply to around 65 percent in early 2026. Competition is intense and well funded, including Ro, LifeMD, Teladoc, and numerous smaller GLP-1 telehealth providers, which can raise customer-acquisition costs. Growth decelerated to roughly 4 percent year over year in the first quarter of 2026 even as the valuation stayed rich relative to current profitability, so any further slowdown or margin erosion could weigh on the stock. The company also carries dependence on a few high-demand categories and on continued heavy marketing spend.
Is HIMS a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not advice. The bull case is a growing subscription base, category expansion, and 2030 revenue targets. The bear case is decelerating growth near 4 percent, gross margins compressed to about 65 percent, GLP-1 regulatory risk, and a rich valuation versus current profits. Weigh both against your own plan.
What does Hims & Hers do?
+
Hims & Hers runs a direct-to-consumer telehealth platform. Users complete an online consultation, connect with licensed providers, and receive personalized prescription and wellness products shipped on a recurring subscription. Categories include sexual health, hair loss and dermatology, mental health, women's health, and weight management. Most revenue comes from auto-refilling monthly subscriptions rather than one-time purchases.
Does HIMS pay a dividend?
+
No. Hims & Hers does not pay a dividend. Like most growth-stage companies, it reinvests cash into marketing, category expansion, vertical integration such as pharmacies and manufacturing, and other initiatives. Any return from owning the shares would come from price changes rather than dividend income. Check a current quote if you need to confirm dividend status before investing.
How does Hims & Hers make money?
+
It earns most revenue from recurring monthly subscriptions for personalized prescription and over-the-counter products. Customers pay for ongoing treatment plans across conditions like hair loss, sexual health, mental health, and weight management. Higher-priced specialty offerings and owning more of the supply chain, including affiliated pharmacies, support revenue and aim to improve unit economics over time.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell HIMS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.